一家号称用互联网改造传统医药流通的企业，在盈利增长的情况下，股价却跌穿了发行价，市值蒸发超过300亿。这不是市场的非理性，而是一 场商业模式的彻底败退。 2025年12月17日，药师帮股价收盘于5.62港元。这家曾经市值超过400亿港元的"医药B2B第一股"，如今市值仅剩38亿港元，较2023年8月的历史高点跌去超 过90%。 更令人困惑的是，在公司营收和净利润持续增长的背景下，股价却一路向南。2025年中报显示，药师帮营收98.43亿元，同比增长11.7%，净利润7811.7万 元，同比激增258%。 市场似乎已经看穿了某种本质：药师帮的盈利增长不是来自效率提升，而是源于一种不可持续且可能触碰监管红线的模式。 01 业务模式，从"平台"到"伪平台"的异化过程 药师帮成立于2015年，创始人是前搜房网CTO张步镇。它最初的目标是搭建一个连接药品供应商与终端药店的数字化平台，解决院外医药市场信息不对称、 渠道混乱的问题。 传统的医药流通模式是线性的：药企→总代理→省级经销商→地市级经销商→药店/医疗机构。每个环节都会加价，导致终端价格高企。 一位广东连锁药店老板的经历极为典型：他发现自己通过药师帮采购的"帮力健 ...

Group 1 - The core viewpoint of the articles revolves around the integration of AIGC (Artificial Intelligence Generated Content) in vocational education, emphasizing its role in enhancing the quality and digital transformation of education [1][2] - The conference held in Dalian was attended by nearly 200 representatives from over 150 vocational institutions, indicating a strong interest in the topic of AI in education [1] - The company presented a report titled "AIGC Empowers the Whole Process of Talent Cultivation, Supporting the Digital Transformation of Education," highlighting the practical experience in utilizing big data, large models, and AI to improve various educational processes [1] Group 2 - The company aims to explore new paths for the deep integration of AIGC and education, supporting vocational institutions in achieving high-quality and connotative development during the "14th Five-Year Plan" period [2] - As of the end of the reporting period, the company reported a backlog of orders amounting to 430 million yuan, with over 130 million yuan specifically for teaching and examination orders [2] - The company’s self-developed "Starry Sky Education Model" has been registered with the National Internet Information Office, achieving an 80% accuracy rate in generating course knowledge graphs, and has been implemented in several schools in Beijing and Shanghai [1]

Core Insights - Leo International Group has successfully completed the transfer of control of a company listed on the Frankfurt Stock Exchange, now renamed Leo International Precision Health Aktiengesellschaft (LIPH AG), marking the first Taiwanese company to list on this exchange [1][10] - The company aims to leverage its new listing to expand into the European market, focusing on a "Precision Health Trinity" strategy that includes AI-driven pharmaceuticals, diagnostics, and community healthcare services [5][10] Group 1: Company Strategy and Positioning - The company plans to establish a Single Family Office (SFO) in Singapore, reflecting its commitment to long-term family legacy and investment in the healthcare sector [8][13] - The "Precision Health Trinity" strategy will focus on AI-driven solutions for both common and rare diseases, aiming for rapid expansion through non-organic growth strategies [5][10] - The company holds 80% of the shares in LIPH AG, with original shareholders converting their shares to enjoy liquidity in the international capital market [10][11] Group 2: Market Trends and Opportunities - Singapore is positioned as a hub for family offices, with over 2,000 SFOs expected by 2024, driven by a stable political environment and tax incentives [3] - The German biotechnology and medical technology sectors saw investments of €1.6 billion in the first nine months of 2024, a 70% increase year-on-year, indicating a growing interest in the health industry [3] - The digital pathology market is projected to grow from $8.1 billion in 2024 to $19.5 billion by 2031, highlighting the accelerating shift towards technology-driven precision health [3] Group 3: Future Plans and Global Expansion - The company is exploring dual listing in the U.S. and potential listing in Singapore to enhance its market presence [7][11] - Future strategies include attracting international sovereign funds and multinational capital groups to invest in the precision health platform [5][11] - The CEO emphasizes the importance of optimizing corporate governance and financial flexibility to support sustainable global operations [11]